Compare KRNY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KRNY | CTNM |
|---|---|---|
| Founded | 1884 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.9M | 480.5M |
| IPO Year | 2014 | 2024 |
| Metric | KRNY | CTNM |
|---|---|---|
| Price | $8.13 | $12.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $8.50 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 256.1K | 253.2K |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.65% | N/A |
| EPS Growth | ★ 130.22 | 0.46 |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,580,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $17.52 | N/A |
| P/E Ratio | $25.95 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $5.76 | $3.35 |
| 52 Week High | $8.50 | $16.33 |
| Indicator | KRNY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 47.21 |
| Support Level | $7.77 | $11.54 |
| Resistance Level | $8.33 | $13.26 |
| Average True Range (ATR) | 0.22 | 0.58 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 83.64 | 51.94 |
Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.